NOW APPROVED

ONCE-WEEKLY
wegovy™
semaglutide injection 2.4 mg

Step-by-step guide to

Wegovy™ Coverage and Savings

PAY $25

Eligible* patients can take advantage of a special $25 offer for up to 6 fills

*Eligibility and restrictions apply. For six 28-day fills for eligible commercially insured patients with coverage for branded anti-obesity medications, whose coverage is confirmed via a benefits verification. Novo Nordisk reserves the right to modify or cancel this program at any time. See terms and conditions at wegovyterms2021.com.

Indications and Usage

Wegovy™ (semaglutide) injection 2.4 mg is indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of ≥30 kg/m^2 (obesity) or ≥27 kg/m^2 (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia).

Limitations of Use

- Wegovy™ contains semaglutide and should not be coadministered with other semaglutide-containing products or with any GLP-1 receptor agonist.
- The safety and effectiveness of Wegovy™ in combination with other products intended for weight loss, including prescription drugs, over-the-counter drugs, and herbal preparations, have not been established.
- Wegovy™ has not been studied in patients with a history of pancreatitis.

Important Safety Information

WARNING: RISK OF THYROID C-CELL TUMORS

- **In rodents, semaglutide causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors at clinically relevant exposures. It is unknown whether Wegovy™ causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of semaglutide-induced rodent thyroid C-cell tumors has not been determined.**
- **Wegovy™ is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Counsel patients regarding the potential risk for MTC with the use of Wegovy™ and inform them of symptoms of thyroid tumors (e.g. a mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with Wegovy™.**

Contraindications

- Wegovy™ is contraindicated in patients with a personal or family history of MTC or in patients with MEN 2, and in patients with a prior serious hypersensitivity reaction to semaglutide or to any of the excipients in Wegovy™. Serious hypersensitivity reactions, including anaphylaxis and angioedema have been reported with semaglutide.

Please see additional Important Safety Information throughout.
Click here for Prescribing Information, including Boxed Warning, for Wegovy™.
Click here for Prescribing Information, including Boxed Warning, for Saxenda® (liraglutide) injection 3 mg.

novo nordisk®

ONCE-WEEKLY
wegovy™
semaglutide injection 2.4 mg

STEP 1: **COVERAGE**

Check coverage eligibility in minutes

Your patients with Saxenda® (liraglutide) injection 3 mg coverage may be eligible for a special Wegovy™ savings offer

Go to **WegovyCoverage.com** to verify your patients' pharmacy benefits. If your patients have coverage for Saxenda®, they may be eligible for the special Wegovy™ savings offer.

ALREADY REGISTERED?	NOT REGISTERED YET?
If you have previously registered with NovoCare®, it will only take minutes to enter your patient's information to check coverage.	This one-time registration at NovoCare® allows you to get full access to the coverage tool. You will need to enter your patient's information during registration to check for coverage.

After coverage is confirmed:

- **Send prescriptions to pharmacy**
  - — A new prescription is required for each dose strength
- **Give patients a Wegovy™ patient starter kit**
- **For patients who receive a starter kit, which includes a 1-month supply of four 0.25 mg Wegovy™ pens, record it in the EHR by checking the "samples given" box**
  - — Write prescription for 0.5 mg
  - — Encourage your patients to check in throughout their dose-escalation schedule to assess progress and tolerability

After receiving a pre-populated prior authorization from CoverMyMeds®, please complete and submit it to help your patient with obtaining access to Wegovy™ after the first 6 fills.

EHR, electronic health record.

For your patients *without* Wegovy™ or Saxenda® coverage:

Write a letter to the benefits manager of your patient's human resources (HR) department to request coverage or provide an exception. A sample letter is available at **WegovyPro.com**.

Important Safety Information (cont'd)

Warnings and Precautions

- **Risk of Thyroid C-Cell Tumors:** Patients should be further evaluated if serum calcitonin is measured and found to be elevated or thyroid nodules are noted on physical examination or neck imaging.
- **Acute Pancreatitis:** Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists, including semaglutide. Acute pancreatitis was observed in patients treated with Wegovy™ in clinical trials. Observe patients carefully for signs and symptoms of acute pancreatitis (including persistent severe abdominal pain, sometimes radiating to the back, and which may or may not be accompanied by vomiting). If acute pancreatitis is suspected, discontinue Wegovy™ promptly, and if acute pancreatitis is confirmed, do not restart.
- **Acute Gallbladder Disease:** In clinical trials, cholelithiasis was reported by 1.6% of Wegovy™ patients and 0.7% of placebo patients. Cholecystitis was reported by 0.6% of Wegovy™ patients and 0.2% of placebo patients. If cholelithiasis is suspected, gallbladder studies and appropriate clinical follow-up are indicated.
- **Hypoglycemia:** Wegovy™ lowers blood glucose and can cause hypoglycemia. In a trial of patients with type 2 diabetes, hypoglycemia was reported in 6.2% of Wegovy™ patients versus 2.5% of placebo patients. Patients with type 2 diabetes taking Wegovy™ with an insulin secretagogue (e.g. sulfonylurea) or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia. Inform patients of the risk of hypoglycemia and educate them on the signs and symptoms. Monitor blood glucose in patients with type 2 diabetes.

Please see additional Important Safety Information throughout.
Click here for Prescribing Information, including Boxed Warning, for Wegovy™.
Click here for Prescribing Information, including Boxed Warning, for Saxenda® (liraglutide).

ONCE-WEEKLY
wegovy™
semaglutide injection 2.4 mg

STEP 2: **SAVINGS**

Help eligible* patients obtain the special savings offer

Eligible* patients will pay $25 per 28-day prescription for up to 6 fills

*Eligibility and restrictions apply. For six 28-day fills for eligible commercially insured patients with coverage for branded anti-obesity medications, whose coverage is confirmed via a benefits verification. Novo Nordisk reserves the right to modify or cancel this program at any time. See terms and conditions at wegovyterms2021.com.

For patients with Saxenda® (liraglutide) injection 3 mg coverage:

Complete the Wegovy™ savings request form available from your Novo Nordisk representative or download at **GetWegovy.com** and fax it to the NovoCare® Live Hub

Patients with a prior authorization will still benefit from these savings

Forward the savings offer to your patients—you'll receive it from the NovoCare® Live Hub within 4 hours

The NovoCare® Live Hub will also call patients the following day (and email if requested by patients) to confirm they received their personalized savings offer, to verify they have enrolled, and to provide details on the program

Remind your patients to activate the savings offer at SaveOnWegovy.com and have them provide their "activated" savings offer to the pharmacy when picking up their prescription

For your patients *without* Wegovy™ or Saxenda® coverage:

If your patients pay cash, they can receive savings of up to $200 at NovoCare.com for their Wegovy™ prescription.

Patients paying $25 may need to step back their dose.
Eligible† patients can pay as little as $0 by calling 1-833-4-WEGOVY.

Questions? Contact your Novo Nordisk representative or call the NovoCare® Live Hub at 1-888-809-3942.
8:00 AM to 8:00 PM ET, Monday–Friday

†Eligibility and restrictions apply. For eligible commercially insured patients currently using another Wegovy™ co-pay card offer, if such patients are prescribed a dose de-escalation within 21 days after the date of fill for the original dose. Maximum benefit of an additional $25 off the patient's existing co-pay offer. Novo Nordisk reserves the right to modify or cancel this program at any time. See terms and conditions at wegovyterms2021.com.

Important Safety Information (cont'd)

Warnings and Precautions (cont'd)

- **Acute Kidney Injury:** There have been postmarketing reports of acute kidney injury and worsening of chronic renal failure, which in some cases required hemodialysis, in patients treated with semaglutide. Patients with renal impairment may be at a greater risk of acute kidney injury, but some events have been reported in patients without known underlying renal disease. A majority of the events occurred in patients who experienced nausea, vomiting, or diarrhea, leading to volume depletion. Monitor renal function when initiating or escalating doses of Wegovy™ in patients reporting severe adverse gastrointestinal reactions and in patients with renal impairment reporting any adverse reactions that could lead to volume depletion.
- **Hypersensitivity:** Serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) have been reported with semaglutide. If hypersensitivity reactions occur, discontinue use of Wegovy™, treat promptly per standard of care, and monitor until signs and symptoms resolve. Use caution in a patient with a history of anaphylaxis or angioedema with another GLP-1 receptor agonist.
- **Diabetic Retinopathy Complications in Patients with Type 2 Diabetes:** In a trial of patients with type 2 diabetes, diabetic retinopathy was reported by 4.0% of Wegovy™ patients and 2.7% of placebo patients. Rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy. Patients with a history of diabetic retinopathy should be monitored for progression of diabetic retinopathy.
- **Heart Rate Increase:** Mean increases in resting heart rate of 1 to 4 beats per minute (bpm) were observed in Wegovy™ patients compared to placebo in clinical trials. More Wegovy™ patients compared with placebo had maximum changes from baseline of 10 to 19 bpm (41% versus 34%) and 20 bpm or more (26% versus 16%). Monitor heart rate at regular intervals and instruct patients to report palpitations or feelings of a racing heartbeat while at rest. If patients experience a sustained increase in resting heart rate, discontinue Wegovy™.

Please see additional Important Safety Information throughout.
Click here for Prescribing Information, including Boxed Warning, for Wegovy™.
Click here for Prescribing Information, including Boxed Warning, for Saxenda®.

ONCE-WEEKLY
wegovy™
semaglutide injection 2.4 mg

WeGo*Together*™

Enroll your patients in WeGo*Together*™

Start your patients on the right track with personalized support

This program helps your patients get started and stay on track with Wegovy™. It includes behavior modification tools and gives patients access to:

- Savings options for Wegovy™
- Direct access to a Health Coach who provides:
  - Tips to help patients stay on track
  - Assistance with using the Wegovy™ pen
  - Support to help your patients manage their weight
  - Motivation to make lifestyle changes
- Choice of live phone coaching or text/email-based coaching (same Coach throughout the program)
- A personalized web portal where patients can track or log their weekly dose, set goals, and share their weight progress with their Coach



Patients can get started at **WegovySupport.com**

Important Safety Information (cont'd)

Warnings and Precautions (cont'd)

- **Suicidal Behavior and Ideation:** Suicidal behavior and ideation have been reported in clinical trials with other weight management products. Monitor patients for depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior. Discontinue Wegovy™ in patients who experience suicidal thoughts or behaviors and avoid in patients with a history of suicidal attempts or active suicidal ideation.

Adverse Reactions

- The most common adverse reactions reported in ≥5% of patients treated with Wegovy™ are nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, dyspepsia, abdominal distention, dizziness, eructation, gastroenteritis, flatulence, hypoglycemia in patients with type 2 diabetes, and gastroesophageal reflux disease.

Drug Interactions

- The addition of Wegovy™ in patients treated with insulin has not been evaluated. When initiating Wegovy™, consider reducing the dose of concomitantly administered insulin secretagogues (such as sulfonylureas) or insulin to reduce the risk of hypoglycemia.
- Wegovy™ causes a delay of gastric emptying and has the potential to impact the absorption of concomitantly administered oral medications. Monitor the effects of oral medications concomitantly administered with Wegovy™.

Use in Specific Populations

- **Pregnancy:** May cause fetal harm. When pregnancy is recognized, discontinue Wegovy™. Discontinue Wegovy™ in patients at least 2 months before a planned pregnancy.

Please see additional Important Safety Information throughout.
Click here for Prescribing Information, including Boxed Warning, for Wegovy™.
Click here for Prescribing Information, including Boxed Warning, for Saxenda® (liraglutide) injection 3 mg.

ONCE-WEEKLY
wegovy™
semaglutide injection 2.4 mg